These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 8620675

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry.
    Pian P, Labovitz E, Hoffman K, Clavijo CF, Rzasa Lynn R, Galinkin JL, Vinks AA, Malik P, Christians U.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct 15; 937():79-83. PubMed ID: 24029553
    [Abstract] [Full Text] [Related]

  • 23. Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.
    Granneman GR, Braeckman RA, Erdman KA.
    Clin Pharmacokinet; 1995 Oct 15; 29 Suppl 2():1-8. PubMed ID: 8620665
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects.
    Vlase L, Popa A, Neag M, Muntean D, Leucuta SE.
    Clin Drug Investig; 2012 Aug 01; 32(8):533-8. PubMed ID: 22765768
    [Abstract] [Full Text] [Related]

  • 26. Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
    Awni WM, Granneman GR, Locke CS, Brandwein SR, Dube LM.
    Eur J Clin Pharmacol; 1995 Aug 01; 48(2):155-60. PubMed ID: 7589031
    [Abstract] [Full Text] [Related]

  • 27. The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects.
    Marino MR, Langenbacher KM, Hammett JL, Nichola P, Uderman HD.
    J Clin Psychopharmacol; 1997 Feb 01; 17(1):27-33. PubMed ID: 9004054
    [Abstract] [Full Text] [Related]

  • 28. Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo.
    Sirois P, Borgeat P, Lauzière M, Dubé L, Rubin P, Kesterson J.
    Agents Actions; 1991 Sep 01; 34(1-2):117-20. PubMed ID: 1665285
    [Abstract] [Full Text] [Related]

  • 29. Effect of fluconazole on the disposition of phenytoin.
    Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ.
    Clin Pharmacol Ther; 1991 Apr 01; 49(4):420-5. PubMed ID: 2015731
    [Abstract] [Full Text] [Related]

  • 30. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration.
    Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Kokwaro GO.
    Br J Clin Pharmacol; 2002 Dec 01; 54(6):635-42. PubMed ID: 12492612
    [Abstract] [Full Text] [Related]

  • 31. Effect of 'Mentat' on the pharmacokinetics of single and multiple doses o phenytoin in rabbits.
    Garg SK, Islam AS, Kumar N, Sehgal M, Bhargava VK.
    Neurol India; 1999 Jun 01; 47(2):104-7. PubMed ID: 10402333
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of Paeoniae Radix, a traditional Chinese medicine, on the pharmacokinetics of phenytoin.
    Chen LC, Chou MH, Lin MF, Yang LL.
    J Clin Pharm Ther; 2001 Aug 01; 26(4):271-8. PubMed ID: 11493369
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E, Cohn J, Dubé L, Drazen JM.
    JAMA; 1996 Mar 27; 275(12):931-6. PubMed ID: 8598621
    [Abstract] [Full Text] [Related]

  • 37. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
    Machinist JM, Kukulka MJ, Bopp BA.
    Clin Pharmacokinet; 1995 Mar 27; 29 Suppl 2():34-41. PubMed ID: 8620669
    [Abstract] [Full Text] [Related]

  • 38. Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base.
    Burstein AH, Fisher KM, McPherson ML, Roby CA.
    Pharmacotherapy; 2000 May 27; 20(5):562-7. PubMed ID: 10809343
    [Abstract] [Full Text] [Related]

  • 39. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
    Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson LJ, Boodhoo TI, Wright S, Dubé LM, Dahlén SE.
    Am J Respir Crit Care Med; 1998 Apr 27; 157(4 Pt 1):1187-94. PubMed ID: 9563738
    [Abstract] [Full Text] [Related]

  • 40. Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses.
    Soma LR, Uboh CE, Guan F, Birks EK, Teleis DC, Rudy JA, Tsang DS, Watson AO.
    Am J Vet Res; 2001 Apr 27; 62(4):483-9. PubMed ID: 11327452
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.